Compare SVRE & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRE | SBFM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.3M |
| IPO Year | 2021 | 2008 |
| Metric | SVRE | SBFM |
|---|---|---|
| Price | $3.03 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 36.6K | ★ 437.6K |
| Earning Date | 05-12-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,305,891.00 |
| Revenue This Year | $1,793.31 | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.11 |
| 52 Week Low | $0.55 | $0.25 |
| 52 Week High | $6.30 | $3.05 |
| Indicator | SVRE | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 33.03 |
| Support Level | $2.80 | $1.13 |
| Resistance Level | $3.18 | $1.28 |
| Average True Range (ATR) | 0.37 | 0.15 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 7.21 | 16.67 |
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.